Hims & Hers Stock Just Fell 30 Percent While Its CEO Feuded With Novo Nordisk
The companies engaged in an increasingly heated war of words on Monday following the drugmaker’s decision to end a collaboration.

The companies engaged in an increasingly heated war of words on Monday following the drugmaker’s decision to end a collaboration.